|Generic Name||Brand Name|
Adalimumab is given as a shot under the skin (subcutaneous injection).
Adalimumab reduces the effects of tumour necrosis factor (TNF). TNF is produced in your body in times of inflammation and attaches to the joint surface, causing damage to soft tissues, cartilage, and bones. Adalimumab is a disease-modifying antirheumatic drug (DMARD), which means it slows the progression of conditions such as rheumatoid arthritis and ankylosing spondylitis. DMARDs are also called immunosuppressive drugs or slow-acting antirheumatic drugs (SAARDs).
Adalimumab is used to treat adults who have inflammatory conditions such as rheumatoid arthritis or ankylosing spondylitis. Adalimumab may be used alone or in combination with other DMARDs such as methotrexate.
Adalimumab appears to work rapidly and is well tolerated.
Rheumatoid arthritis. A clinical trial of adalimumab used in combination with methotrexate found a 20% improvement in 67% of people who were given the medicine, with improvements noticeable after 1 week of treatment.1 In another study of adalimumab used alone, researchers report significant, rapid, sustained reductions in disease activity and improved physical function, including reduced swelling and pain.2
The most common side effect of TNF antagonists, such as adalimumab, is an allergic reaction to the injection (shot). If you have a reaction to the shot, it will happen right away, either during the shot or within 1 to 2 hours after the shot. Your doctor may give you medicines to prevent or stop the reaction.
Symptoms of a reaction to the shot include:
Warnings about serious side effects of TNF antagonists have been issued. The U.S. Food and Drug Administration (FDA) and the drug’s manufacturers have warned about:
See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)
Adalimumab is significantly more expensive than DMARDs such as methotrexate and sulfasalazine.
Adalimumab should not be used by pregnant women or women of child-bearing age who are not using reliable birth control. If you are going to take adalimumab, you should be on some form of reliable birth control. If you plan to become pregnant, check with your doctor before stopping birth control and trying to become pregnant.
- Weinblatt ME, et al. (2003). Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody alpha for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis and Rheumatism, 48(1): 35–45.
- Van de Putte LBA, et al. (2004). Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of the Rheumatic Diseases, 63(5): 508–516.
- Van er Heijde D, et al. (2006). Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis and Rheumatism, 54(7): 2136–2146.
- Davis JC, et al. (2007). Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. Arthritis and Rheumatism, 57(6): 1050–1057.
Last Revised: April 30, 2012
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information.